Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis

AI Briefing

• – BRIUMVI reduces relapse rates and MRI activity in highly active multiple sclerosis
• – Significant reduction in no evidence of disease activity (NEDA-3) with BRIUMVI compared to teriflunomide
• – TG Therapeutics announces new data from ULTIMATE I and II studies of BRIUMVI in highly active relapsing multiple sclerosis